The prognostic value of plasma soluble ST2 in hospitalized Chinese patients with heart failure

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Zhang, Rongcheng ^a   Zhang, Yuhui ^a   Zhang, Jian ^a   An, Tao ^a   Huang, Yan ^a   Guo, Xiao ^a   Januzzi, James L ^b   Cappola, Thomas P ^c   Yin, Shijie ^a   Wang, Yunhong ^a   Zhou, Qiong ^a   Zou, Changhong ^a   Ji, Shiming ^a   Lv, Rong ^a  

^a FUWAI HOSPITAL   (China)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; MEMBRANE PROTEIN; ST2 PROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ARTICLE; BLOOD ANALYSIS; CAUSE OF DEATH; CHINA; CHINESE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; SURVIVAL RATE; AGED; BLOOD; COHORT ANALYSIS; COMORBIDITY; HOSPITALIZATION; MIDDLE AGED; MORTALITY;

ADULT; AGED; BIOLOGICAL MARKERS; CAUSE OF DEATH; CHINA; COHORT STUDIES; COMORBIDITY; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PATIENT OUTCOME ASSESSMENT; PEPTIDE FRAGMENTS; PROGNOSIS; RECEPTORS, CELL SURFACE;

EID: 84908565990     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110976     Document Type: Article

References (28)

1. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, et al. (2003) Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289: 194-202.
2. Fang J, Mensah GA, Croft JB, Keenan NL (2008) Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 52: 428-434.
3. Kociol RD, Hammill BG, Fonarow GC, Klaskala W, Mills RM, et al. (2010) Generalizability and longitudinal outcomes of a national heart failure clinical registry: Comparison of Acute Decompensated Heart Failure National Registry (ADHERE) and non-ADHERE Medicare beneficiaries. Am Heart J 160: 885-892.
4. Giamouzis G, Kalogeropoulos A, Georgiopoulou V, Laskar S, Smith AL, et al. (2011) Hospitalization epidemic in patients with heart failure: risk factors, risk prediction, knowledge gaps, and future directions. J Card Fail 17: 54-75.
5. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, et al. (2004) Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 109: 2186-2190.
6. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, et al. (2008) Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 117: 1936-1944.
7. Rehman SU, Mueller T, Januzzi JL Jr (2008) Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 52: 1458-1465.
8. Pascual-Figal DA, Manzano-Fernandez S, Boronat M, Casas T, Garrido IP, et al. (2011) Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 13: 718-725.
9. Boisot S, Beede J, Isakson S, Chiu A, Clopton P, et al. (2008) Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail 14: 732-738.
10. Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, et al. (2008) Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 54: 752-756.
11. Ky B, French B, McCloskey K, Rame JE, McIntosh E, et al. (2011) High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 4: 180-187.
12. Januzzi JL Jr, Peacock WF, Maisel AS, Chae CU, Jesse RL, et al. (2007) Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 50: 607-613.
13. Socrates T, deFilippi C, Reichlin T, Twerenbold R, Breidhardt T, et al. (2010) Interleukin family member ST2 and mortality in acute dyspnoea. J Intern Med 268: 493-500.
14. Bayes-Genis A, de Antonio M, Vila J, Penafiel J, Galan A, et al. (2013) Head-to-head comparison of two myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 vs. Galectin-3. J Am Coll Cardiol.
15. (2007) Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. Guidelines for the diagnosis and management of chronic heart failure. Zhonghua Xin Xue Guan Bing Za Zhi 35: 1076-1095.
16. (2010) Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology Practice Guideline. Guideline for diagnosis and treatment of acute heart failure. Zhonghua Xin Xue Guan Bing Za Zhi 38: 195-208.
17. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, et al. (2006) Recommendations for chamber quantification. Eur J Echocardiogr 7: 79-108.
18. Moons KG, de Groot JA, Linnet K, Reitsma JB, Bossuyt PM (2012) Quantifying the added value of a diagnostic test or marker. Clin Chem 58: 1408-1417.
19. Pencina MJ, D'Agostino RB Sr, Steyerberg EW (2011) Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 30: 11-21.
20. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, et al. (2005) Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149: 209-216.
21. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ (2005) Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293: 572-580.
22. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, et al. (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479-490.
23. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, et al. (2007) IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 117: 1538-1549.
24. Manzano-Fernandez S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL (2011) Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 107: 259-267.
25. Allen LA, Felker GM, Pocock S, McMurray JJ, Pfeffer MA, et al. (2009) Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail 11: 170-177.
26. Wu AH, Levy WC, Welch KB, Neuberg GW, O'Connor CM, et al. (2013) Association between bilirubin and mode of death in severe systolic heart failure. Am J Cardiol 111: 1192-1197.
27. Ambrosy AP, Vaduganathan M, Huffman MD, Khan S, Kwasny MJ, et al. (2012) Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. Eur J Heart Fail 14: 302-311.
28. Manzano-Fernandez S, Januzzi JL, Pastor-Perez FJ, Bonaque-Gonzalez JC, Boronat-Garcia M, et al. (2012) Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompens ated heart failure. Cardiology 122: 158-166.